New to Meducation?
Sign up
Already signed up? Log In

Category

Preview
0
0

Two thirds of rheumatology patients wait too long for assessment, audit finds

Two thirds of patients with early inflammatory arthritis are not seen by a specialist within the recommended three weeks of referral, says a national clinical audit of rheumatoid and early inflammatory arthritis in England and Wales.1  
feeds.bmj.com
over 4 years ago
Preview
0
0

Two thirds of rheumatology patients wait too long for assessment, audit finds

Two thirds of patients with early inflammatory arthritis are not seen by a specialist within the recommended three weeks of referral, says a national clinical audit of rheumatoid and early inflammatory arthritis in England and Wales.1  
feeds.bmj.com
over 4 years ago
Preview
0
6

Paracetamol: Ineffective for Spinal Pain and Osteoarthritis

While paracetamol continues to be prescribed as an initial treatment for osteoarthritis and back pain, this comprehensive meta-analysis found little evidence for its use in these conditions.  
medscape.com
over 4 years ago
Preview
0
0

Gout: Colchicine Linked to Reduced CV Risk

Colchicine use was associated with a 49% lower risk for cardiovascular events and a 73% reduction in all-cause mortality in patients with gout.  
medscape.com
over 4 years ago
Preview
0
4

Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden

Objective To investigate the risk of squamous cell and basal cell skin cancer in patients with rheumatoid arthritis naive to biologic drugs, in patients starting tumour necrosis factor (TNF) inhibitor treatment, and in the general population.  
feeds.bmj.com
over 4 years ago
Preview
0
0

Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden

Objective To investigate the risk of squamous cell and basal cell skin cancer in patients with rheumatoid arthritis naive to biologic drugs, in patients starting tumour necrosis factor (TNF) inhibitor treatment, and in the general population.  
feeds.bmj.com
over 4 years ago
Preview
0
0

Rheumatoid arthritis, TNF inhibitors, and non-melanoma skin cancer

Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the two most common types of non-melanoma skin cancer. Epidemiological studies have indicated that the incidence of non-melanoma skin cancers is higher in patients with rheumatoid arthritis than in the general population.1 2 Further concerns exist that immunosuppression contributes to an increased prevalence of these malignancies. Specifically, organ transplantation and the concomitant use of immunosuppressive agents is strongly associated with SCC and to a lesser extent with BCC.3 4 Tumor necrosis factor (TNF) inhibitors are the most commonly used biological immunosuppressive agents for treatment of rheumatoid arthritis. Pooled data from 74 randomized controlled trials showed that TNF inhibitors were associated with an increase in risk of non-melanoma skin cancer beyond the risk associated with rheumatoid arthritis alone.5 Several large observational studies have supported this finding,6 7 but others have not.8 9 …  
feeds.bmj.com
over 4 years ago
Preview
0
0

Rheumatoid arthritis, TNF inhibitors, and non-melanoma skin cancer

Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the two most common types of non-melanoma skin cancer. Epidemiological studies have indicated that the incidence of non-melanoma skin cancers is higher in patients with rheumatoid arthritis than in the general population.1 2 Further concerns exist that immunosuppression contributes to an increased prevalence of these malignancies. Specifically, organ transplantation and the concomitant use of immunosuppressive agents is strongly associated with SCC and to a lesser extent with BCC.3 4 Tumor necrosis factor (TNF) inhibitors are the most commonly used biological immunosuppressive agents for treatment of rheumatoid arthritis. Pooled data from 74 randomized controlled trials showed that TNF inhibitors were associated with an increase in risk of non-melanoma skin cancer beyond the risk associated with rheumatoid arthritis alone.5 Several large observational studies have supported this finding,6 7 but others have not.8 9 …  
feeds.bmj.com
over 4 years ago
Preview
0
0

The use of drugs to manage symptoms in people with arthritis related to cystic fibrosis | Cochrane

Arthritis is not a common complication of cystic fibrosis, but it can be a major complication when it does occur. There are two distinct types of arthritis in cystic fibrosis: cystic fibrosis-related arthropathy and hypertrophic pulmonary osteoarthropathy. The best treatment for these conditions is not clear because of the underlying disease and its intense treatment. We planned to report evidence from clinical studies to evaluate the effectiveness and safety of different anti-inflammatory analgesic drugs compared with placebo, with each other or with no treatment. However, we were disappointed that we could not find any completed randomised controlled studies of these treatments or any evidence from non-randomised controlled studies. One study in cystic fibrosis-related arthropathy has finished and may provide some evidence when published. We suggest that there should be a randomised controlled study to look at the effects and the safety of using anti-inflammatory drugs or painkillers or both to manage the symptoms of cystic fibrosis-related arthritis. This is an update of a previously published review (date of last search 19 January 2016). Since no studies have been included in the review up until January 2016, we will still search for studies every two years, but will not publish an updated version of this review until we can include any new studies.  
cochrane.org
over 4 years ago
Preview
0
2

Apremilast Effective for Psoriatic Arthritis

Apremilast improves clinical outcomes in patients with psoriatic arthritis and active psoriasis, according to results from the PALACE 3 randomized controlled trial.  
medscape.com
over 4 years ago
Preview
0
0

FDA Staff Supports Celltrion's Biosimilar Remicade

U.S. Food and Drug Administration staff members on Friday said clinical data from Celltrion Inc's biosimilar form of blockbuster arthritis drug Remicade indicated it is "highly similar" to the branded product in terms of safety, purity and potency.  
medscape.com
over 4 years ago
Preview
0
0

The Genetics of Rheumatoid Arthritis

This review examines the genetic and environmental risk factors that influence the development of rheumatoid arthritis.  
medscape.com
over 4 years ago
Preview
0
0

Impact of Certolizumab Pegol in Rheumatoid Arthritis

How effective is certolizumab pegol in the treatment of rheumatoid arthritis? This study takes a look at patient-reported outcomes as well as clinical measures of disease activity.  
medscape.com
over 4 years ago
Preview
0
2

Lesinurad (Zurampic) for Gout Approved in European Union

As in the United States, regulators required postmarketing studies to further assess the renal and cardiovascular safety profile of the drug.  
medscape.com
over 4 years ago
Preview
0
0

Evidence for Treating Rheumatoid Arthritis to Target

When managing rheumatoid arthritis, does a treat-to-target approach convey better outcomes than routine care?  
medscape.com
over 4 years ago
Preview
0
4

Oral Steroids, NSAIDs Equally Safe, Effective for Acute Gout

A large, multicenter randomized trial found that oral prednisolone and oral indomethacin were equally effective at reducing acute gout pain in patients presenting to emergency departments.  
medscape.com
over 4 years ago
Preview
0
0

The Link Between Sleep Apnea and Gout

Dr Deane discusses a recent study that found an association between incident gout and sleep apnea, providing further evidence for a link between cardiopulmonary physiology and hyperuricemia.  
medscape.com
over 4 years ago
Preview
0
0

Biosimilar Infliximab: One Step Closer to the Pharmacy?

Dr Jonathan Kay shares his experience at the recent FDA Arthritis Advisory Committee meeting on approval of biosimilar infliximab.  
medscape.com
over 4 years ago
Preview
0
0

Rituximab Done: What's Next in Rheumatoid Arthritis?

Which biologic therapy is most effective after rituximab in rheumatoid arthritis patients?  
medscape.com
over 4 years ago
Preview
0
0

Mucosal Immune Tolerance in Rheumatoid Arthritis

Does rheumatoid arthritis originate as mucosal inflammation in an extra-articular location? Read why many believe this is the case.  
medscape.com
over 4 years ago